Vaccine approaches and immunological aspects of SARS-CoV-2 with Professor Katie Flanagan

https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/b5/51/e7/b551e72b-bc7a-a10a-b90a-95f919c6b41a/mza_10872013384498953585.jpg/600x600bb.jpg

COVID19 Road to a vaccine

MVEC

18 episodes

8 months ago

The year 2020 has seen the emergence of the SARS-CoV-2 virus (COVID19), a unique and potentially devastating virus, with no known prevention or treatment. This new SARS-CoV-2 virus has shown to not only have significant international health implications, but also immense psychological and economic impacts. Associate Professor Nigel Crawford, a vaccinologist and consultant paediatrician at the Murdoch Children’s Research Institute (MCRI) & Royal Children’s Hospital (RCH), Melbourne, will delve into the global pursuit of a safe and effective vaccine to prevent COVID19. This is all occurring at ‘pandemic speed’ and MVEC’s new podcast will explore this complicated and multi-faceted process through interviews with a variety of national and international vaccine experts.

Medicine

Health & Fitness

RSS

All content for COVID19 Road to a vaccine is the property of MVEC and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/89a7f3d037c7a3c66e8b53401be97e50.jpg

Vaccine approaches and immunological aspects of SARS-CoV-2 with Professor Katie Flanagan

COVID19 Road to a vaccine

31 minutes

5 years ago

Vaccine approaches and immunological aspects of SARS-CoV-2 with Professor Katie Flanagan

In episode 8 of our COVID19 Road to a vaccine series, our host, Associate Professor Nigel Crawford, speaks with Professor Katie Flanagan. Katie is Head of Infectious Diseases at Launceston General Hospital and is affiliated with the University of Tasmania, Monash University and RMIT where she is involved in a broad range of research projects, with her main interests being in vaccinology and infectious diseases immunology. She has led a number of vaccine immunology trials. In this episode they discuss:

•Immunological aspects of SARS-CoV-2
•Vaccine responses in adults versus children and the difference in adult immune systems
•Vaccinology strategies being used in the development of a SARS-CoV-2 vaccine
•Antibody response variation by age
•Viral vector vaccines and how they work
•Novel vaccine approaches and the implications of these on vaccine safety including: mRNA and DNA SARS-CoV-2 vaccines

Links:

VACSIG: Vaccination Special Interest Group
https://www.asid.net.au/groups/vacsig

The Lancet: Immunogenicity and safety of recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults ages 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext

The Lancet: Safety and immunogenicity of the ChAdOx1 nCOV-19 vaccine against SARS-CoV-2: a preliminary report of a phase ½, single-blind, randomised controlled trial
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext

WHO draft landscape of COVID-19 candidate vaccines:
https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

COVID-19 Vaccine tracker
https://www.covid-19vaccinetracker.org/